Aware Super Pty Ltd as trustee of Aware Super Has $42.82 Million Stock Holdings in Johnson & Johnson $JNJ

Aware Super Pty Ltd as trustee of Aware Super cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 280,352 shares of the company’s stock after selling 4,484 shares during the quarter. Aware Super Pty Ltd as trustee of Aware Super’s holdings in Johnson & Johnson were worth $42,824,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in JNJ. Nuveen LLC bought a new position in Johnson & Johnson in the first quarter valued at about $1,369,188,000. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after acquiring an additional 2,825,626 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after acquiring an additional 2,557,388 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in Johnson & Johnson during the second quarter worth about $401,420,000. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. UBS Group raised their target price on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday. Argus set a $210.00 target price on Johnson & Johnson in a report on Wednesday. Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $199.59.

Johnson & Johnson Trading Up 0.6%

NYSE:JNJ opened at $193.27 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market capitalization of $465.45 billion, a PE ratio of 18.65, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. The business’s 50-day simple moving average is $180.49 and its 200-day simple moving average is $164.80.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.